ORIGENIS
Origenis provides small molecule drug discovery services. It offers drug design, chemical synthesis, and biological characterization services combined with its proprietary small molecule drug discovery technology platform. Its technology platforms include MOREsystem and MolMind which provide direct exploitation of huge chemical spaces and delivers straightforward synthetic routes generating patentable drug candidates in less time.
ORIGENIS
Industry:
Biotechnology Pharmaceutical
Founded:
2005-01-01
Address:
Martinsried, Bayern, Germany
Country:
Germany
Website Url:
http://www.origenis.de
Total Employee:
11+
Status:
Active
Contact:
+498978016760
Email Addresses:
[email protected]
Technology used in webpage:
Euro OVH Envoy 3 To 9 CcTLD Redirects
Similar Organizations
FNP Clinical
FNP Clinical is a contract Research Organisation offering comprehensive set of services for Phase I-IV clinical trials in Russia.
Optimed SA
Optimed SA is a contract research organization, provides services in clinical research.
Total Scientific
Total Scientific is a contract research organisation that specialises in providing biomarker-related services to the pharmaceutical
Viroclinics Biosciences
Viroclinics Biosciences is a contract research and clinical laboratory service company providing diagnostic and preclinical studies.
Zelmic
Zelmic is a contract research organization dedicated to local delivery of small molecules, peptides and proteins
Official Site Inspections
http://www.origenis.de Semrush global rank: 5.25 M Semrush visits lastest month: 1.56 K
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Origenis"
Team | Origenis | Planegg
Prior Origenis, as Head of Molecular Modeling at Morphochem, he invented protein- and ligand-based drug design methods, QSPR, parallel evolutionary search algorithms, and multiparametric optimization techniques, that together โฆSee details»
Origenis GmbH - Innovations- und Gründerzentrum โฆ
Origenis was founded in October 2005 through a management buy-out by Michael Almstetter, Dr. Michael Thormann, and Dr. Andreas Treml, who decided to continue the development and โฆSee details»
Origenis - Crunchbase Company Profile & Funding
Origenis is a contract research organisation offering services in drug design, synthesis, and characterisation.See details»
Origenis GmbH (DE) - Life-Sciences-Europe.com
Origenis (Group) Predecessor: Morphochem (Group) Industry: drug discovery services: Person: Almstetter, Michael (Origenis 202012 Managing Director) Person 2: Thormann, Michael โฆSee details»
Biotech company Origenis welcomes Prof. Hendrik Liebers as โฆ
The industry expert will play a key role in supporting the companyโs strategic development. July 23, 2023Origenis is a technology platform-based biotech company located at the IZB that โฆSee details»
Origenis GmbH - Innovations- und Gründerzentrum โฆ
Origenis wurde im Oktober 2005 durch einen Management-Buy-out von Michael Almstetter, Dr. Michael Thormann und Dr. Andreas Treml gegründet, die sich entschlossen, die Entwicklung โฆSee details»
origenis GmbH Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for origenis GmbH of Planegg, Bayern. Get the latest business insights from Dun & Bradstreet. D&B Business โฆSee details»
Origenis - Products, Competitors, Financials, Employees, โฆ
Origenis.de. Overview & Products; People; About Origenis. Origenis is a biotechnology company focused on the development of small molecule therapeutics. The company leverages AI โฆSee details»
Origenis Company Profile - Office Locations, Competitors ... - Craft
Origenis has 5 employees at their 1 location. See insights on Origenis including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Origenis Company Profile 2024: Valuation, Investors, โฆ
Origenis General Information Description. Developer of small molecule kinase inhibitors for CNS disorders. The company develops a brain-penetrating highly selective small molecule medicines and diagnostics for a variety of โฆSee details»
Biotech company Origenis welcomes Prof. Hendrik Liebers as โฆ
As an experienced manager and expert in the biotech and pharma scene, he enriches our team with his valuable expertise and supports us in strategic implementation,โ said Dr. Michael โฆSee details»
Biotech-Firma Origenis begrüßt Prof. Hendrik Liebers als Chairman โฆ
โOrigenis hat über einen Zeitraum von mehr als 15 Jahren eine Technologiesuite und Kompetenz im Bereich Medizinalchemie auf Weltklasseniveau aufgebaut. Es gibt in der europäischen โฆSee details»
Origenis (und Leukocare) unter die Top10 Europäischen Drug
May 3, 2019 Mit diesem parallelen Ansatz für neue Kandidaten spart Origenis erheblich Zeit und Geld und verbessert die Erfolgswahrscheinlichkeit bei der Entdeckung von niedermolekularen โฆSee details»
AI Innovation Platform | Origenis | Planegg
Our AI-driven drug design and synthesis planning engine combines soft-synthesis planning fed by >150,000 reaction rules applied to existing in-house and commercial building blocks, state-of โฆSee details»
More documents for Origenis (Group) - Life-Sciences-Europe.com
BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) EuropaBio aisbl โ the European Association of Bioindustries; BioIndustry Association (BIA) โฆSee details»
origenis GmbH (origenis GmbH) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ๆ่่ฅ โฆ
Abstract Purpose AT04A and AT06A are two AFFITOPE® peptide vaccine candidates being developed for the treatment of hypercholesterolemia by inducing proprotein convertase โฆSee details»
Careers | Origenis | Planegg
Origenis hires people with a passion to make a difference to the health of millions of people globally. top of page. Our Work. Our Vision; What we do; How we work; Where we come from; โฆSee details»
Origenis featured on the cover of Pharma Tech Outlook Drug โฆ
April 26, 2019 A new approach to small molecule drug discoveryA multipart AI-based, drug discovery platform, optimising compounds for specificity, efficacy, physiochemical properties, โฆSee details»
Drug Pipeline | Origenis | Planegg
Our drug pipeline consists of preclinical small molecule drugs that are designed to hit select targets with high potency and outstanding selectivity in difficult-to-reach tissues of interest like โฆSee details»